Aptadir Therapeutics raises $42.8M Seed (Italy, Oct 2026)
Reach the investors backing rounds like this
Backed by CE-Ventures · verified emails and LinkedIn on Datapile
Aptadir Therapeutics Raises €40 Million Seed Round - Startupbusiness.it
Aptadir Therapeutics is developing a new class of RNA inhibitor-based therapeutics called DNMTs Interacting RNAs (DiRs) to address genetic disorders and oncology. Their platform aims to reactivate silenced genes and restore normal biological functions, potentially offering a way to treat previously irreversible genetic diseases. This seed round will advance their lead candidate for Fragile X Syndrome towards clinical development.
Aptadir Therapeutics Raises €40 Million Seed Round Startupbusiness.it
| Sep 21, 2026 | Dalfilo | $2.0M | — | Italy |
| Sep 16, 2026 | Biorsaf | $5.2M | — | Italy |
| Sep 15, 2026 | Exein | $270.0M | Series C | Italy |
| Sep 10, 2026 | Equixly API Security | $10.0M | Series A | Italy |
6,694 investors back startups in Italy
You just read who funded Aptadir Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.